åœç«ç²Ÿç¥ã»ç¥çµå»çç ç©¶ã»ã³ã¿ãŒ(NCNP)ãªãã³ã«é沢倧åŠã¯ãåã©ãæä»£ã®æ ç·çèåŸ (æŽèšãªã©ã®å¿ççèåŸ )ãæäººåŸã®ã泚æãã€ã¢ã¹å€åæ§ãã«é¢é£ããããšãæããã«ããããã«ãã®ã¡ã«ããºã ã«ççããBDNFéºäŒåããé¢äžããå¯èœæ§ãèŠåºãããšå ±åã§çºè¡šããã
åææã¯ãNCNP 粟ç¥ä¿å¥ç ç©¶æã®éåæŽæé·ãåã»è¡åå»åŠç ç©¶éšã®å åŒæå®€é·ãåã»äŒè€çå©åç ç©¶å¡(çŸã»åæµ·éå€§åŠ ç°å¢å¥åº·ç§åŠç ç©¶æè²ã»ã³ã¿ãŒ ç¹ä»»å©æ)ãåã»æææç ç©¶å¡ãNCNP ç¥çµç ç©¶æ çŸç ç 究第äžéšã®ååæµ©åéšé·(çŸã»åžäº¬å€§åŠå»åŠéš 粟ç¥ç¥çµç§åŠè¬åº§ ææ)ãéæ²¢å€§ åœéåºå¹¹æè²é¢(èšåºèªç¥ç§åŠç 究宀)ã®æŸäºäžæææãã®å ±åç ç©¶ããŒã ã«ãããã®ã詳现ã¯ãåœé粟ç¥å»åŠèªãTranslational Psychiatryãã«ãªã³ã©ã€ã³æ²èŒãããã
å¹Œå°æã«èåŸ ããã©ãŠãäœéšãçµéšãããšããã¬ãã£ããªæ å ±ã«å¯ŸããŠéåºŠã«æ³šæãåãããšããæ³šæãã€ã¢ã¹ã匷ããªãããããšèããããŠãããããããã®äžæ¹ã§ããã¬ãã£ããªæ å ±ã«å¯ŸããŠéã«æ³šæãé床ã«éžããããããªããšããå ±åããªãããããšããããèŠè§£ãåãããŠãããšããã
ããã§å ±åç ç©¶ããŒã ã¯ãå¹Œå°æã«èåŸ äœéšãåãããšããã¬ãã£ããªæ å ±ã«å¯Ÿããããæã«ã¯æ³šæãé床ã«åãããŸãããæã«ã¯æ³šæãé床ã«éžãããšãã£ããããªããã¬ãã£ããªæ å ±ã«å¯Ÿããæ³šæã®åãæ¹ãäžå®å®ã§äžè²«æ§ããªããªããæ³šæãã€ã¢ã¹å€åæ§ããåããã®ã§ã¯ãªãããšèå¯ã
ãã®çç±ã¯ãçåœãè ãããããªææäœéšãçµãã®ã¡ã«çºçããããšã®ãããå¿çå€å·åŸã¹ãã¬ã¹é害(PTSD)ãæ£è ã§ã¯ãããããæ³šæãã€ã¢ã¹å€åæ§ã倧ããããšãç¥ãããŠããããã ããã®ãããªæ³šæã®äžå®å®ãªåãæ¹ã«ãã£ãŠããã©ãŠãã«é¢é£ããçç¶ã匷ãŸãããšãæ³å®ãããŠããããã ãšããã
ããã§ä»åãããããã»ãããŒã課é¡ããšããæ³šæãã€ã¢ã¹ãæããå®éšèª²é¡ãçšããŠãå¥åžžæäººã«ãããå¹Œå°æè¢«èåŸ äœéšãšæ³šæãã€ã¢ã¹ããã³ãã®å€åæ§ã®é¢é£ã«ã€ããŠãå ±åç ç©¶ããŒã ã®ç«ãŠãä»®èª¬ã®æ€èšŒãè¡ãããã
ãããŠãNCNPã䞻幹ç ç©¶æ©é¢ãšããŠå ±åç ç©¶æ©é¢ãšãšãã«å®æœããŠããã²ãã ã»ãã€ãªããŒã«ãŒã»å¿çèšåºææšãå å«ãããã©ãŠã/PTSDç ç©¶ãããžã§ã¯ãã«ãããŠåéäžã®ããŒã¿ããã³ãµã³ãã«ã®äžéšãçšããŠå®æœãããã
ãŸã被éšè ã¯ã128åã®å¥åžžæäººå¥³æ§ãã©ã³ãã£ã¢ã察象ãšãããå¹³å幎霢ã¯36.4æ³(ç¯å²:20ïœ64æ³)ã§ãå šå¡ãæ¥æ¬èªãæ¯åœèªãšãããå被éšè ã«å¯ŸããŠç°¡æçãªæ§é å颿¥ãè¡ããã粟ç¥çŸæ£ã«çœ¹æ£ããŠããªãããšã確èªãããããã§å®æœãããã
ããã«ã被éšè ã®å¹Œå°æè¢«èåŸ äœéšã¯ãèªèšåŒè³ªåçŽã§ããå¹Œå°æãã©ãŠã質å祚(Childhood Trauma Questionnaire)ã«ãã£ãŠè©äŸ¡ã宿œããããæ³šæãã€ã¢ã¹ãšãã®å€åæ§ããããã»ãããŒã課é¡ã«ããæž¬å®ã§ãããããã«æ¡è¡ãè¡ãããè¡æ¶²äžã®ççæ§ç©è³ªã§ãããè «ç壿»å å-α(TNF-α)ãããã€ã³ã¿ãŒãã€ãã³-6(IL-6)ãããé«æåºŠC-reactive protein(CRP)æ¿åºŠããæž¬å®ãããšãšãã«ãè¡æ¶²ããDNAãæœåºããŠPCRæ³ã«ããBDNFéºäŒåVal66Metå€åã®è§£æãè¡ãããã
ã¡ãªã¿ã«ãããã»ãããŒã課é¡ã¯ããŸãã¢ãã¿ãŒäžã«èŠèŠåºæ¿ã®ãã¢(ä»åã¯ãäžç«èªããšããã¬ãã£ãèªã)ãæç€ºããããã®çŽåŸããã¢ã®ãããããšåãäœçœ®ã«ãåå¿ãã¹ãåºæ¿(=ãããŒããä»åã¯ãâããŸãã¯ãâã)ãæç€ºãããã被éšè ã¯ããã®ãããŒãã«éãæ£ç¢ºã«åå¿ãããšããå 容ã (ä»åã¯ãâããŸãã¯ãâãã®ããŒãæŒããŠããã)ã
ä»®ã«æ³šæãã€ã¢ã¹ããããšããã°ããã¬ãã£ãèªãšåãäœçœ®ã«çŽåŸã«çŸãããããŒãã«å¯ŸããŠã¯çŽ æ©ãåå¿ãããã(åå¿æéãçã)ããäžç«èªãšåãäœçœ®ã«çŽåŸã«çŸãããããŒãã«å¯ŸããŠã¯åå¿ã«æéãããã(åå¿æéãé·ã)ãšäºæ³ãããããã®ããã2ã€ã®åå¿æéã®å·®ã泚æãã€ã¢ã¹ã®çšåºŠãšèããããšãå¯èœã ãšãããæ³šæãã€ã¢ã¹å€åæ§ã¯ãäžäººã²ãšãã®ç ç©¶åå è ã«ã€ããŠå®éšå šäœã8ã€ã®åºéã«åããŠååºéã®æ³šæãã€ã¢ã¹ãæ±ãããããã®ããã§åºéã®éã«ããããã€ã¢ã¹å€åã®å€§ãã(=æšæºåå·®)ãšããŠæ±ããããã
ããã«ãããã«é¢é£ããçç©åŠçã¡ã«ããºã ã調ã¹ããããççãšãèšæ¶ã»åŠç¿ã«éèŠãªåãããããè³ç±æ¥ç¥çµæ é€å å(BDNF:brain-derived neurotrophic factor)éºäŒåãã«ãçç®ãBDNFéºäŒåã¯ãç¥çµçްèã®æé·ãçåãã·ããã¹ã®æ©èœãç¥çµäŒéãªã©ã調ç¯ããã¿ã³ãã¯è³ªãã³ãŒãããéºäŒåã ãšããã
ããã¯ãå¹Œå°æãã©ãŠãã«ãã£ãŠèº«äœã®è»œåºŠæ ¢æ§ççãæ¹èµ·ãããããšããççãšBDNFéºäŒåã¯ããããèªç¥æ©èœã«é¢é£ããããšã瀺ãããŠããããã ãšãããäŸãã°å ±åç ç©¶ããŒã ã®å è¡ç ç©¶ã«ãããŠããPTSDæ£è ã«ãããŠBDNFéºäŒåã®ãäžå¡©åºå€å(SNP)ãã®ãVal66Metå€åããèšæ¶ãã€ã¢ã¹ã«é¢é£ããããšã瀺ãããŠãããšãããVal66Metå€åã¯ã66çªã¢ããé žãããªã³(Val)ããã¡ããªãã³(Met)ã«çœ®ãæããå€åã®ããšã§ã现èããã®BDNFåæ³äœäžã«ã€ãªããæ©èœå€åã§ãããçš®ã ã®ç²Ÿç¥çŸæ£ãèšæ¶ã»åŠç¿ã»æ³šææ©èœãšã®é¢é£ãå ±åãããŠããã
çµæãšããŠãå¹Œå°ææ ç·çèåŸ ãšæ³šæãã€ã¢ã¹å€åæ§ã®éã«ææãªæ£ã®çžé¢ãèªãããããšãã(p=0.002)ããããå ±åç ç©¶ããŒã ã®åœåã®ä»®èª¬ãæ¯æãããã®ãšãªã£ããšããã
-

å¹Œå°ææ ç·çèåŸ ã¯ã泚æãã€ã¢ã¹å€åæ§ãšææãªæ£ã®çžé¢ã瀺ãããšã確èªããã (åºæ:NCNP Webãµã€ã)
è¡äžTNF-αæ¿åºŠããæ³šæãã€ã¢ã¹å€åæ§ãšææãªæ£ã®çžé¢ã瀺ãããšã確èªããã(Spearman's Ï = 0.302, p < 0.001)ãããã«å¯Ÿããè¡äžIL-6æ¿åºŠãšé«æåºŠCRPæ¿åºŠã«ã€ããŠã¯ã泚æãã€ã¢ã¹ã泚æãã€ã¢ã¹å€åæ§ãšã¯ææãªçžé¢ã瀺ããªãã£ããšããã
ããã«ãBDNFéºäŒåVal66Metå€åã®Met察ç«éºäŒåãå€ãæããã»ã©ã泚æãã€ã¢ã¹å€åæ§ãææã«å€§ãããªãããšããŸãMetå€åãæãã人ãå¹Œå°ææ ç·çèåŸ ãçµéšããããšã§ã泚æãã€ã¢ã¹å€åæ§ãããã«å€§ãããªãããšã瀺ããããšãããŠããã
-

(a)Val/Val矀(n=40)ãVal/Met矀(n=52)ãMet/Met矀(n=15)ã®éã§æ³šæãã€ã¢ã¹å€åæ§ãæ¯èŒããããããããããã«éããç®±ã²ãå³ãã¢ã¹ã¿ãªã¹ã¯ã¯ãMet察ç«éºäŒåã®æ°ãå¢ããã«ã€ã泚æãã€ã¢ã¹å€åæ§ãææã«å€§ãããªãããšã瀺ãããŠãã(p=0.021:Jonckheere-Terpstra trend testã«ãã)ã(b)泚æãã€ã¢ã¹å€åæ§ã«ã€ããŠã®ãVal66Metå€åãšå¹Œå°ææ ç·çèåŸ ã®äº€äºäœçšã被éšè ã¯ãChildhood Trauma Questionnaireã®æ ç·çèåŸ é ç®ã®ã«ãããªãåŸç¹(8/9)ã«åºã¥ãããæ ç·çèåŸ ããããããã¯ãæ ç·çèåŸ ãªãã矀ã«åé¡ãããããšã©ãŒããŒã¯æšæºèª€å·®ã瀺ãããã®ãã¢ã¹ã¿ãªã¹ã¯ã¯ãVal66Metå€åãšå¹Œå°ææ ç·çèåŸ ã®äº€äºäœçšãææã§ããããšã瀺ãããŠãã(p=0.022:2å é çœ®åæ£åæã«ãã) (åºæ:NCNP Webãµã€ã)
ãªããä»åã®ç ç©¶ã®æçŸ©ã«ã€ããŠå ±åç ç©¶ããŒã ã¯ãå¥åžžæäººå¥³æ§ã«ãããŠå¹Œå°æã®æ ç·çèåŸ äœéšã泚æãã€ã¢ã¹å€åæ§ã«é¢é£ããããšãåããŠèŠåºããç¹ã«ãããšããŠããããŸãããã®ã¡ã«ããºã ã«ççãBDNFéºäŒåå€åãé¢äžããå¯èœæ§ã«ã€ããŠã瀺ãããçµæã«ã€ããŠãBDNFéºäŒåå€åã®Met察ç«éºäŒåã¯ãVal察ç«éºäŒåã«æ¯ã¹ãŠæ³šæãã€ã¢ã¹å€åæ§ã倧ãããšããçµæãåŸãããããããã¯Valã«æ¯ã¹Metã¯çްèããã®BDNFåæ³äœäžãåãããããšèãããããšããŠããããããã®ææãããšã«ãä»åŸãç·æ§äŸã§ã®æ€èšã®ã»ããæ³šæãã€ã¢ã¹å€åæ§ã®æ²»çæ³ã«ã€ããŠã®ç ç©¶ãé²ãããšãæåŸ ããããšããŠããã
